DexCom (DXCM) to Release Quarterly Earnings on Thursday

DexCom (NASDAQ:DXCM) will issue its quarterly earnings data after the market closes on Thursday, April 25th. Analysts expect the company to announce earnings of $0.27 per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.07. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The firm had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same quarter last year, the firm posted $0.34 EPS. The business’s revenue was up 26.9% on a year-over-year basis. On average, analysts expect DexCom to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

DexCom Trading Up 0.6 %

Shares of NASDAQ:DXCM opened at $131.52 on Tuesday. DexCom has a 1 year low of $74.75 and a 1 year high of $142.00. The firm has a market capitalization of $50.70 billion, a price-to-earnings ratio of 100.40, a price-to-earnings-growth ratio of 2.25 and a beta of 1.20. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48. The business’s 50 day moving average price is $129.81 and its 200-day moving average price is $117.38.

Analyst Upgrades and Downgrades

DXCM has been the topic of a number of recent analyst reports. UBS Group increased their target price on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. StockNews.com raised DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Citigroup increased their price objective on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Raymond James increased their price objective on DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research note on Tuesday, January 23rd. Finally, Royal Bank of Canada began coverage on DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $141.40.

Insiders Place Their Bets

In related news, CFO Jereme M. Sylvain sold 3,363 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the sale, the chief financial officer now directly owns 71,142 shares of the company’s stock, valued at approximately $8,304,405.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Jereme M. Sylvain sold 3,363 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the sale, the chief financial officer now directly owns 71,142 shares of the company’s stock, valued at approximately $8,304,405.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 20,321 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total value of $2,715,088.81. Following the sale, the executive vice president now directly owns 80,441 shares of the company’s stock, valued at $10,747,722.01. The disclosure for this sale can be found here. Insiders sold 189,375 shares of company stock valued at $25,530,859 in the last three months. 0.41% of the stock is currently owned by insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.